glp 1 neuroprotection Neuroprotective effects of GLP-1 class drugs in Parkinson's disease PDF] Novel dual GLP-1/GIP receptor

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound).

Join us at our Weight Loss Event, Wednesday, December 4th, and discover how we may help make your path to weight loss quick, easy, and affordable

Yale researchers have discovered that GLP-1 receptor agonist drugs, like Ozempic and Wegovy, may offer promising new ways of treating alcohol use disorder.

This diet focuses on foods that complement GLP-1 medications, enhancing their effectiveness in managing appetite and improving metabolism

Supports appetite control throughout the day